James C. Foster, a director at Charles River Laboratories International, Inc. (NASDAQ: CRL), has reduced his direct ownership in the company through a significant sale of common stock. The transaction, which totaled $16,875,000, involved the disposition of 75,000 shares priced at $225.00 per share. The sale was reported on June 29, 2026, and was executed pursuant to a Rule 10b5-1 trading plan that Foster adopted on March 6, 2026. Following this transaction, Foster directly holds 31,596 shares of Charles River Laboratories common stock.
The timing of the sale is notable given the stock's recent performance. CRL shares have been trading near their 52-week high of $228.88, with the stock currently valued at $229.09. Over the past year, the stock has delivered a 47% return, reflecting strong market momentum. According to InvestingPro analysis, CRL appears overvalued at its current price levels. Investors seeking deeper insights can access a comprehensive Pro Research Report, which covers CRL and over 1,400 other US equities.
Beyond his direct holdings, Foster maintains indirect ownership of common stock through various trusts and Grantor Retained Annuity Trusts (GRATs). These indirect holdings include 10,780 shares via a 2025 GRAT, 20,000 shares via a 2026 GRAT, 155,611 shares held by a trust, 10,000 shares held by a trust for his spouse, and 5,423 shares via a 2024 GRAT.
While Foster's sale reduces his direct stake, Charles River Laboratories has been the subject of positive analyst sentiment. Argus has raised its price target to $250, citing the company's strategic moves in mergers and acquisitions. Morgan Stanley upgraded Charles River to Overweight from Equalweight, increasing its price target to $220, driven by an increase in biopharma funding that translates into new business opportunities. CLSA also upgraded the stock to Outperform, raising the target to $219, based on a favorable regulatory outlook in both China and the U.S.
On the operational front, Charles River Laboratories announced the expansion of its AI-enabled digital pathology platform. The platform aims to reduce pathology timelines by at least one week while adhering to industry standards. The platform integrates advanced AI tools for quality control and digital pathology reviews. Jefferies has highlighted the role of AI in driving cost reductions in drug development, which could impact companies like Charles River. These developments reflect Charles River's continued focus on innovation and strategic growth.
Investors considering CRL can evaluate its potential using ProPicks AI, which assesses the stock alongside thousands of other companies using over 100 financial metrics. The AI evaluates fundamentals, momentum, and valuation to identify risk-reward opportunities, with notable past winners including Super Micro Computer (+185%) and AppLovin (+157%).